Untitled 3

Source R&D is the authoritative source of technology and services information supporting pharmaceutical and biotechnology companies in their drug discovery and development research projects.

Source R&D features extensive listings of service providers classified under company or organisation type, including contract chemical manufacturers; contract biologics manufacturers; biological research companies and organisations; and companies and organisations providing advisory, consultancy, legal, regulatory and other services.

The extensive coverage of Source R&D and the support of life sciences organisations One Nucleus and Bionow make it an invaluable reference tool that streamlines the vendor selection process to bring pharmaceutical/biotechnology companies and suppliers together.

Irvine Scientific introduces chemically-defined natural killer cell expansion medium for immunotherapy and translational research applications

Cell culture media specialist Irvine Scientific has introduced PRIME-XV® NK Cell CDM as the first commercially available chemically-defined (CDM), animal component-free (ACF) medium for the ex-vivo expansion of NK cells while preserving cell potency and functionality. Current approaches to immunotherapy focus…
  • Published in Source R&D
  • Read: 241 times

TTP Plc and Cubed Laboratories complete NESDEP portable laboratory project

TTP Plc and DNA-based molecular diagnostic devices and test kits developer Cubed Laboratories have completed a project to develop Cubed’s core product, the NESDEP portable laboratory for pathogen detection. This accurate, high-throughput and easy-to-use system has a number of applications…
  • Published in Source R&D
  • Read: 237 times

TxCell appoints Lonza as CAR-Treg cellular product manufacturer

TxCell SA, a developer of cellular immunotherapies based on regulatory T cells (Tregs) for inflammation, autoimmunity and transplantation, and Lonza Pharma & Biotech have entered into a Master Service Agreement for the manufacture of TxCell’s HLA-A2 CAR-Treg cellular product (TX200)…
  • Published in Source R&D
  • Read: 230 times

IONTAS and aTen Therapeutics in oncology collaboration

IONTAS Limited, a specialist in the discovery and optimisation of fully human antibodies,and aTen Therapeutics Limited, a biopharmaceutical company developing next-generation antibodies for the treatment of cancer, have entered into a strategic collaboration in which IONTAS will use its proprietary…
Subscribe to this RSS feed